Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Clinical trial NCT04662710 · COMPLETED
Trial details
- NCT number
- NCT04662710
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-30
- Primary completion
- 2024-10-29
- Enrollment
- 895
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.